DB16268InvestigationalGene Therapies
Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
- Also known as
- Dna (recombinant vaccinia virus strain livp clone gl-onc1) · DNA (synthetic vaccinia virus oncolytic-strain GLV-1h68 (complete genome)) · Olvi-Vec
- Code names
- GL-ONC1 · GLV-1H68
Resolves to
Compound
What you can answer from here — as of January 15, 2026
Which companies are running trials of Olvimulogene nanivacirepvec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account